We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
- Recent AMAM Stock Price: $11.54
- Yearly Gain for AMAM stock: 2291.84%
- Market Cap for AMAM stock: ―
- P/E Ratio for AMAM stock: -34.719
Will AMAM's stock price go up? Is there an accurate AMAM stock forecast available?
TipRanks.com reports that Ambrx Biopharma currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $22.25. The target pricing ranges from a high AMAM forecast of $26 down to a low forecast of $15. Ambrx Biopharma (AMAM)’s last closing stock price was $11.54 which would put the average price target at 118.11% upside.
In addition, TradingView issued a buy rating for AMAM stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on AMAM stock.
Other analysts covering AMAM include:
- Reni Benjamin of JMP Securities issued a Buy rating with the price target of $15 on 2 days ago
- Kaveri Pohlman of BTIG issued a Buy rating with the price target of $26 on 3 days ago
- Joel Beatty of Robert W. Baird issued a Buy rating with the price target of $22 on 2 weeks ago
If you are wondering if AMAM is a good stock to buy, here are 3rd party ratings for AMAM stock:
- TipRanks.com: Strong Buy
- TradingView.com: buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Sell, Top 18% (45 out of 251)
What is the sentiment on the street regarding Ambrx Biopharma? (Current ratings compiled by TipRanks.com)
- News Sentiment for AMAM stock: Very Bullish
- Blogger Consensus for AMAM stock: Bullish
- Media Buzz for AMAM stock: High
- Insider Signal for AMAM stock: Positive
- Investor Sentiment for AMAM stock: Very Negative
- Hedge Fund signal for AMAM stock: Neutral
The stock market is extremely volatile, and you need to do your own research on AMAM stock including scouring the social networks like AMAM StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AMAM stock chart >>
Summary: Acelyrin Inc. is a clinical biopharma company. It focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep. Acelyrin Inc. is based in Agoura Hills, California.
- Recent SLRN Stock Price: $6.72
- Yearly Gain for SLRN stock: -72.94%
- Market Cap for SLRN stock: $846.85M
- P/E Ratio for SLRN stock:
Will SLRN's stock price go up? Is there an accurate SLRN stock forecast available?
TipRanks.com reports that ACELYRIN, INC. currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $30.75. The target pricing ranges from a high SLRN forecast of $68 down to a low forecast of $12. ACELYRIN, INC. (SLRN)’s last closing stock price was $6.72 which would put the average price target at 357.59% upside.
In addition, TradingView issued a sell rating for SLRN stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SLRN stock.
Other analysts covering SLRN include:
- Emily Bodnar of H.C. Wainwright issued a Buy rating with the price target of $30 on 3 days ago
- Vikram Purohit of Morgan Stanley issued a Hold rating with the price target of $13 on 3 days ago
- Akash Tewari of Jefferies issued a Buy rating with the price target of $12 on 4 days ago
If you are wondering if SLRN is a good stock to buy, here are 3rd party ratings for SLRN stock:
- TipRanks.com: Strong Buy
- TradingView.com: sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 18% (45 out of 251)
What is the sentiment on the street regarding ACELYRIN, INC.? (Current ratings compiled by TipRanks.com)
- News Sentiment for SLRN stock: Very Bullish
- Blogger Consensus for SLRN stock: Bullish
- Media Buzz for SLRN stock: Medium
- Insider Signal for SLRN stock: ―
- Investor Sentiment for SLRN stock: Very Negative
- Hedge Fund signal for SLRN stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on SLRN stock including scouring the social networks like SLRN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SLRN stock chart >>
Summary: Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
- Recent ARWR Stock Price: $21.20
- Yearly Gain for ARWR stock: -10.00%
- Market Cap for ARWR stock: $3.08B
- P/E Ratio for ARWR stock: -16.925
Will ARWR's stock price go up? Is there an accurate ARWR stock forecast available?
TipRanks.com reports that Arrowhead Pharmaceuticals currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $58.25. The target pricing ranges from a high ARWR forecast of $90 down to a low forecast of $33. Arrowhead Pharmaceuticals (ARWR)’s last closing stock price was $21.20 which would put the average price target at 154.72% upside.
In addition, TradingView issued a Strong sell rating for ARWR stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ARWR stock.
Other analysts covering ARWR include:
- Keay Nakae of Chardan Capital issued a Buy rating with the price target of $60 on 1 day ago
- Luca Issi of RBC Capital issued a Buy rating with the price target of $50 on 2 days ago
- Patrick Trucchio of H.C. Wainwright issued a Buy rating with the price target of $90 on 2 weeks ago
If you are wondering if ARWR is a good stock to buy, here are 3rd party ratings for ARWR stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding Arrowhead Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for ARWR stock: Neutral
- Blogger Consensus for ARWR stock: Bullish
- Media Buzz for ARWR stock: Low
- Insider Signal for ARWR stock: Negative
- Investor Sentiment for ARWR stock: Very Negative
- Hedge Fund signal for ARWR stock: Negative
The stock market is extremely volatile, and you need to do your own research on ARWR stock including scouring the social networks like ARWR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ARWR stock chart >>
Summary: ImmunoGen Inc is a development-stage biotechnology company focused on the development of targeted cancer therapeutics using its proprietary antibody-drug conjugate technology. ImmunoGen's ADC technology is used in three development-stage candidates in its own pipeline, Roche's marketed product, Kadcyla and in development programs of its partners Bayer, Biotest, CytomX, Novartis, Sanofi, Roche, Takeda, Debiopharm & Jazz Pharmaceuticals.'Among ImmunoGen's wholly owned candidates, mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha, is being developed as a single-agent therapy for platinum-resistant ovarian cancer and in combination regimens for both platinum-resistant and platinum-sensitive disease. The candidate is also being developed in combination with other cancer drugs in a mid-stage study.'Pivekimab sunirine is currently under evaluation in early- to mid-stage studies for treatment of patients with acute myeloid leukemia & other CD123-positive hematological malignancies.
- Recent IMGN Stock Price: $29.35
- Yearly Gain for IMGN stock: 209.44%
- Market Cap for IMGN stock: $4.30B
- P/E Ratio for IMGN stock: -53.337
Will IMGN's stock price go up? Is there an accurate IMGN stock forecast available?
TipRanks.com reports that ImmunoGen currently has 3 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $31.00. The target pricing ranges from a high IMGN forecast of $31 down to a low forecast of $31. ImmunoGen (IMGN)’s last closing stock price was $29.35 which would put the average price target at -13.49% upside.
In addition, TradingView issued a Strong buy rating for IMGN stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IMGN stock.
Other analysts covering IMGN include:
- Etzer Darout of BMO Capital issued a Hold rating with the price target of $31 on 1 day ago
- James Shin of Deutsche Bank issued a Hold rating with the price target of $31 on 1 day ago
If you are wondering if IMGN is a good stock to buy, here are 3rd party ratings for IMGN stock:
- TipRanks.com: Hold
- TradingView.com: Strong buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 26% (66 out of 251)
What is the sentiment on the street regarding ImmunoGen? (Current ratings compiled by TipRanks.com)
- News Sentiment for IMGN stock: Very Bullish
- Blogger Consensus for IMGN stock: Bullish
- Media Buzz for IMGN stock: Very High
- Insider Signal for IMGN stock: Neutral
- Investor Sentiment for IMGN stock: Very Positive
- Hedge Fund signal for IMGN stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on IMGN stock including scouring the social networks like IMGN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for IMGN stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
